PMLiVE2d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...
PMLiVE8d
Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis
Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...
PMLiVE8d
LEO Pharma’s Anzupgo cream approved by EC to treat chronic hand eczema
LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the European Commission (EC) to treat adults with moderate-to-severe chronic hand eczema (CHE) for whom topical corticosteroids are ...
PMLiVE9d
Driving behaviour change for positive patient outcomes in pharma
Discover how pharma can help to achieve better patient health outcomes by informing patient behaviour through insights, strategy and collaboration. In the world of healthcare, patient behaviour plays ...
PMLiVE9d
Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation
Pfizer and BioNTech’s updated COVID-19 vaccine targeting the KP.2 strain, a descendant of JN.1, has been recommended by the European Medicines Agency’s human medicines committee for use in individuals ...
PMLiVE9d
Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment
Astellas Pharma’s claudin 18.2-directed cytolytic antibody has been approved by the European Commission (EC) as part of a first-line combination treatment for a subset of gastric cancer patients.
PMLiVE9d
FDA approves Zevra’s Miplyffa as first drug for Niemann-Pick disease type C
The US Food and Drug Administration (FDA) has approved Zevra Therapeutics’ Miplyffa (arimoclomol) to treat Niemann-Pick disease type C (NPC), an ultra-rare lysosomal storage disorder affecting one in ...
PMLiVE10d
Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary cholangitis (PBC). The oral peroxisome proliferator-activated receptor (PPAR) ...
PMLiVE10d
From lab to life: harnessing real-world evidence for informed clinical insights and improved patient outcomes
Picture this: a medicine targeting a particular disease is developed over 12-15 years from initial candidate selection, through to preclinical testing in the labs and to clinical testing in large ...
PMLiVE10d
What is willingness to pay? – Comparing price testing methodologies
Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to explore ...
PMLiVE11d
J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC
Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for a subset of non-small cell lung cancer ...
PMLiVE11d
Wedgewood appoints Danielle Cranwell as president and global agency head
Wedgewood Communications has appointed Danielle Cranwell as president and global agency head to lead the evolution of the agency’s strategic vision and future direction. Cranwell brings more than two ...